It has been five years since Lexicon Pharma's type 1 diabetes therapy, Zynquista, was rejected by the FDA, and it may struggle to have a better outcome at its second attempt. An FDA advisory committee ...

Dezeen Showroom: Italian brand Fiandre aimed to create a "vocabulary of surfaces" with the Lexicon tile collection, featuring eight high-tech stone- and marble-inspired designs. Both atmospheric, ...

Lexicon Pharmaceuticals is positioned for a potential turnaround with three key drug programs and recent partnerships, despite a challenging history. LXRX's sotagliflozin faces uncertain FDA approval ...

Destinations International (DI), the world’s leading association for destination organizations, will proudly mark World Tourism Lexicon Day tomorrow, November 13, with release of the 2025 Tourism ...

For millions of people, a visit to a national park is a chance to escape the everyday and reconnect with the natural world. But have you ever wondered what it’s like to be on the other side of the ...

Ranger's Path: National Park Simulator is an atmospheric simulation that invites players to step into the boots of a national park ranger. Your Ranger Journey Begins In Ranger's Path: National Park ...

Some Dún Laoghaire doors were slammed in canvassing politicians’ faces in advance of the 2014 local elections if they admitted they supported the then yet to open library, according to local ...

An HR advisor with a background in recruitment and HRIS functions, with a passion for video games and writing. Oliver grew up playing Call of Duty with his siblings and has garnered 1000s of hours ...

THE WOODLANDS, Texas — A Houston-area pharmaceutical company has struck a billion-dollar deal with the seller of Ozempic for a potential drug also aiming to combat obesity. Lexicon Pharmaceuticals Inc ...

Lexicon's stock rose 60% after securing a potential $1 billion deal with Novo Nordisk for the preclinical obesity drug LX9851. The company abandoned its underperforming heart failure drug and shifted ...